Search PubMed⌕ Search

Biomedical subjects

G Szabò

Publications and source records attributed to G Szabò.

3 recordsLinked to original sources

Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 maintain functional tolerance to ethanol.

Neurotrophins and growth factors not only affect neuronal development, but also maintain neuronal survival and influence neuronal function in the adult brain, and affect various cognitive processes related to learning and memory. Functional tolerance to ethanol represents an adaptive change in the central nervous system that has been hypothesized to have mechanisms in common with those underlying learning or memory. In the present work, the effects of neurotrophins on ethanol tolerance were compared to the effect of the neuropeptide, arginine vasopressin, which maintains (reduces the rate of dissipation of) both ethanol tolerance and memory. Functional tolerance to ethanol was induced in C57BL/6J mice by feeding them an ethanol-containing liquid diet, and the effect of neurotrophins on the rate of dissipation of tolerance to the hypnotic effect of ethanol was assessed. Human recombinant brain-derived neutrophic factor, neurotrophin-3 and neurotrophin-4/5, injected intracerebroventricularly once daily following ethanol withdrawal, maintained ethanol tolerance, while tolerance dissipated in ethanol-fed mice injected with vehicle (artificial cerebrospinal fluid) or with basic fibroblast growth factor. The results demonstrate that some neurotrophins can modulate neuroadaptation to ethanol, supporting the hypothesis that these factors can influence the function of postmitotic neurons in the adult brain.

Animals↗

CD4 changes conformation upon ligand binding.

Aurintricarboxylic acid (ATA) has been shown to block the binding site for both HIV gp120 and mAb anti-Leu 3a on CD4. We have unexpectedly found that brief treatment with > or = 1 micrograms/ml ATA rapidly disengages another mAb, OKT4E, after it has been bound to CD4 on human PBL. OKT4E is specific for a discontinuous epitope overlapping the MHC class II-binding region in the N-terminal CD4 domain. Interestingly, among 10 other mAb tested, only anti-Leu 8, specific for a leukocyte homing receptor is also quickly released from the cells by ATA treatment. Disengagement of the OKT4E mAb is also seen on a CD4-positive cell line (HPB-ALL) and with recombinant soluble CD4 (sCD4) bound to immobilized OKT4E. In all of these cases, disengagement is prevented if OKT4E is cross-linked, or the Leu 3a site is blocked by the mAb, but not by gp120. Photobleaching fluorescence resonance energy transfer (pFRET) measurements suggest that OKT4E is released as an indirect consequence of ATA-evoked conformational changes of CD4. Similar changes were detected as a result of gp120 binding to PBL. These data raise the possibility of a novel type of immunomodulation: induced disengagement of a bound ligand from its Ag.

Antibodies, Monoclonal↗